WILMINGTON, Del., Dec. 30, 2024 /PRNewswire/ — NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx", the "Company"), a clinical-stage biopharmaceutical company, today announced the transmission of first section of its New Drug Application (NDA) for…Original Article
NRx Pharmaceuticals, Inc. Files Initial Section of U.S. New Drug Application to the FDA for NRX-100 (IV Ketamine) for the Treatment of Suicidal Depression
